Joseph Kim

Inovio CEO Interview: PD1/PDL1 Inhibitors, Immunotherapy And Why Investors Should Be Excited About 2014
Seeking Alpha
Fri, 12/20/13 - 11:49 am
Inovio
Pharma CEOs
PDL-1
immunotherapy
Joseph Kim
Bristol-Myers Squibb
Roche
Dendreon
GSK
ImmunoCellular Therapeutics
Merck
Northwest Biotherapeutics